3 Key Myths About Cannabis Stocks
Myth No. 1: All cannabis stocks are hot.
Cannabis stocks in general are hot right now. It’s wrong, though, to think that all cannabis stocks are performing well. They’re not.
One of the cannabis stocks with the biggest valuations is Insys Therapeutics (NASDAQ: INSY). Insys trades at a market cap of roughly $650 million and won U.S. regulatory approval for its first cannabinoid drug, Syndros. You might think the biotech would be a big winner. Nope. Insys lost around two-thirds of its value in 2016.
Although approval of Syndros was a big positive for Insys, the drug still awaits scheduling by the U.S. Drug Enforcement Administration. In the meantime, Insys’ revenue is falling due to plummeting sales of Subsys, the company’s sublingual fentanyl spray for breakthrough cancer pain.
A corollary of this particular myth is that marijuana stocks that are hot right now will automatically stay hot. Just look at Insys’ track record to debunk this proposition. The stock more than doubled by mid-2015. That’s pretty hot. By the end of the year, though, Insys had given up most of those gains and then experienced its real pain in 2016.
Myth No. 2: Increased acceptance of marijuana is the main driver of all marijuana stocks’ success.
It’s certainly true that use of medical marijuana and recreational use of the drug is becoming more accepted in North America. This increased acceptance has been a major factor in the success of several marijuana stocks.
The share price of Aurora Cannabis (NASDAQOTH: ACBFF), for example, quadrupled in 2016 thanks in part to increased acceptance of medical marijuana in Canada. Aurora began selling medical marijuana in Jan. 2016 and had registered 10,800 active patients by late November.
Aurora’s success, though, didn’t come about just because Canadians were more accepting of medical marijuana. The company took the right steps to reach out to patients and expanded its infrastructure quickly to keep up with demand. Others weren’t so smart and didn’t perform as well as Aurora did.
Some marijuana stocks have achieved success for reasons other than increased public acceptance of marijuana. This is particularly true for biotechs developing cannabinoid drugs. For instance, GW Pharmaceuticals‘ (NASDAQ: GWPH) stock soared in 2016 based on its pipeline success.
In March 2016, GW Pharmaceuticals announced positive results from a late-stage clinical study evaluating its lead cannabinoid product candidate Epidiolex in treating Dravet syndrome, a rare type of epilepsy. The biotech announced more positive results in June from a late-stage study of the drug in treating another rare form of epilepsy known as Lennox-Gastaut syndrome (LGS). GW followed up with additional positive results from another LGS study of Epidiolex in September.
Myth No. 3: All marijuana stocks are extremely risky.
This relative lack of information about the stocks, combined with low trading volumes for many of these stocks, results in added risk for investors seeking to invest in many of the marijuana stocks available. But not every marijuana stock is super-risky.
GW Pharmaceuticals is a good example. It’s not a penny stock. The company appears to have a potential winner on its hands with Epidiolex. GW isn’t a fly by-night venture that recently sprang into existence. The biotech was founded in 1998.
Of course, there’s still a level of risk associated with investing in GW Pharmaceuticals. It’s possible that Epidiolex won’t win regulatory approval. Even if the drug does, it might not perform as well as some expect. However, those are the kinds of risks that any biopharmaceutical stock has.
This article first appeared on Madison.com